Natalizumab and central nervous system lymphoma: No clear association

Annals of Neurology

Volumn 66, Issue 3, 2009, Pages 261-262

  Bozic, Carmen ^a   LaGuette, Julia ^a   Panzara, Michael A ^a   Sandrock, Alfred W ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

B CELL LYMPHOMA; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EDITORIAL; HUMAN; IN SITU HYBRIDIZATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RELAPSE; RISK BENEFIT ANALYSIS;

ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 70350070224     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21835     Document Type: Editorial

References (12)

1. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009;66:403-407.
2. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Human Pathol 2007;38:1293-1304.
3. Bashir R, McManus B, Cunningham C, et al. Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients. J Neurooncol 1994; 20:47-53. (Pubitemid 24299474)
4. Harris NL, Swedlow SH, Frizzera G, Knowles DM. Post transplant lymphoproliterative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:264-270.
5. Hochberg FH, Baehring JM, Hochberg EP. Primary CNS lymphoma. Nat Clin Pract 2007;3:24-35.
6. Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO, et al. Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol 2008;67:1103-1111.
7. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non- Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-1510.
8. DeAngelis LM. Primary central nervous system lymphoma imitates multiple sclerosis. J Neurooncol 1990;9:177-181. (Pubitemid 20319398)
9. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910. (Pubitemid 43313657)
10. Balcer LJ, Galetta SL, Calabresi PA, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007;68:1299-1304. (Pubitemid 46625976)
11. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62:335-346. (Pubitemid 350105948)
12. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8: 254-260.